Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas

Journal of Orthopaedic Science

Volumn 10, Issue 3, 2005, Pages 258-263

  Kawai, Akira ^a   Umeda, Toru ^a   Wada, Takuro ^b   Ihara, Koichiro ^c   Isu, Kazuo ^d   Abe, Satoshi ^e   Ishii, Takeshi ^f   Sugiura, Hideshi ^g   Araki, Nobuhito ^h   Ozaki, Toshifumi ⁱ   Yabe, Hiroo ^j   Hasegawa, Tadashi ^k   Tsugane, Shoichiro ^k   Beppu, Yasuo ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO CANCER CENTER   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

^f CHIBA CANCER CENTER   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HEMATURIA; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SEPSIS; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 21044442548     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-005-0899-3     Document Type: Article

References (27)

1. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic. Hematol Oncol Clin North Am 1995;9:765-85.
2. Loehrer PJ, Sledge GW Jr, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989;7:1655-9.
3. Schutte J, Mouridsen HT, Stewart W, Santoro A, van Oosterom AT, Somers R, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 1990;26:558-61.
4. Casali P, Pastorino U, Azzarelli A, Bertulli R, Zucchinelli P, Devizzi L, et al. Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 1993;31:S228-32.
5. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
6. Leyvraz S, Bacchi M, Cerny T, Lissoni A, Sessa C, Bressoud A, et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Ann Oncol 1998;9:877-84.
7. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45.
8. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8.
9. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-8.
10. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997;15:2378-84.
11. Buesa JM, Lopez-Pousa A, Martin J, Anton A, Garcia del Muro J, Bellmunt J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998;9:871-6.
12. Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221-7.
13. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, et al. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol 1998;9:917-9.
14. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998;21:317-21.
15. Serrone L, Zeuli M, Gamucci T, Nardi M, Cognetti F. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol 2001;47:206-10.
16. Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P, et al. A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. Cancer Chemother Pharmacol 1993;31:S217-21.
17. Culine S, Fabbro M, Assens C, Ychou M, Romieu G, Kramar A, et al. Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors. Ann Oncol 1997;8:951-6.
18. Umeda T, Beppu Y, Yokoyama R, Kito M, Kimura K, Narabayashi I, et al. Multi-institutional study of chemotherapy for malignant soft tissue tumor. J Jpn Orthop Assoc 1999;73:S1359 (in Japanese).
19. Hamada T, Yokoyama R, Umeda T, Masui F, Hasegawa T. Effective chemotherapy (HI-CAV) for advanced high-grade, adult-type soft tissue sarcoma. J Jpn Orthop Assoc 2003;77:S883 (in Japanese).
20. Gottlieb JA, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, et al. Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep 1975;3:271-82.
21. Pinedo HM, Bramwell VH, Mouridsen HT, Somers R, Vendrik CP, Santoro A, et al. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 1984;53: 1825-32.
22. Bui NB, Chauvergne J, Hocke C, Durand M, Brunet R, Coindre JM. Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adriamycin-dacarbazine (CYVADIC) combination. Cancer Chemother Pharmacol 1985;15:82-5.
23. Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987;23:311-21.
24. Carter SK, Livingston RB. Cyclophosphamide in solid tumors. Cancer Treat Rev 1975;2:295-322.
25. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-16.
26. Bramwell VH. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 1997;24:561-71.
27. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-49.